医疗健康大数据应用于老年神经认知功能障碍研究的机会与挑战
摘要
<正>2011年,第11届美国易安信公司(EMC)世界年度大会,大数据概念被正式提出~([1]),标志着人类进入大数据时代。目前比较认同的大数据定义有5V特征,即数据容量巨大(Volume)、生成速度极快(Velocity)、模态多样(Variety)、可变性大(Variability)和真伪难辨(Veracity)~([2]),此定义可能会进一步扩增,比如增加可视化(Visualisation)和科学价值(Value)~([3])。在满足大数据基本特征的前提下,与医疗健康服务目的、过程、结果相关的大数据可以称之为医疗健康大数据。2016年是我国医疗健康大数据元年:3月8日,国家启动精准医学研究重点专
引文
1黄亮.解读大数据和CDO:概念大过实际意义[J]?网络与信息,2013;26(9):24-26.
2 Raghupathi W,Raghupathi V.Big data analytics in healthcare:promise and potential[J].Health Inf Sci Syst,2014;2:3.
3 Fregnac Y.Big data and the industrialization of neuroscience:a safe roadmap for understanding the brain[J]?Science,2017;358(6362):470-7.
4中华人民共和国科学技术部.科技部关于发布国家重点研发计划精准医学研究等重点专项2016年度项目申报指南的通知[EB/OL].http://www.most.gov.cn/tztg/201603/t20160308_124542.htm
5中华人民共和国中央人民政府.国务院办公厅印发《关于促进和规范健康医疗大数据应用发展的指导意见》[EB/OL].http://www.gov.cn/xinwen/2016-06/24/content_5085211.htm
6 Castro-Chavira SA,Fernandez T,Nicolini H,et al.Genetic markers in biological fluids for aging-related major neurocognitive disorder[J].Curr Alzheimer Res,2015;12(3):200-9.
7 Chan KY,Wang W,Wu JJ,et al.Epidemiology of Alzheimer's disease and other forms of dementia in China,1990-2010:a systematic review and analysis[J].Lancet,2013;381(9882):2016-23.
8 Alzheimr's Association.2015 Alzheimer's disease facts and figures[J].Alzheimers Dementia J Alzheimers Assoc,2015;11(3):332-84.
9 World Alzheimer Report 2015.The global impact of dementia[EB/OL].http://www.worldalzreport 2015.org
10谭琳.中国人口老龄化发展趋势预测研究报告[J].中国妇运,2007;(2):15-8.
11秦晓明.神经内科门诊患者认知障碍的横断面调查研究[J].中国现代药物应用,2014;(8):234-5.
12 Lehallier B,Essioux L,Gayan J,et al.Alzheimer's disease neuroimaging initiative.Combined plasma and cerebrospinal fluid signature for the prediction of midterm progression from mild cognitive impairment to Alzheimer disease[J].JAMA Neurol,2016;73(2):203-12.
13 Sosa AL,Albanese E,Stephan BC,et al.Prevalence,distribution,and impact of mild cognitive impairment in Latin America,China,and India:a 10/66 population-based study[J].PLoS Med,2012;9(2):e1001170.
14 Jack CR Jr,Therneau TM,Wiste HJ,et al.Transition rates between amyloid and neurodegeneration biomarker states and to dementia:a population-based,longitudinal cohort study[J].Lancet Neurol,2016;15(1):56-64.
15 Pase MP,Beiser A,Aparicio H,et al.Interarm differences in systolic blood pressure and the risk of dementia and subclinical brain injury[J].Alzheimers Dement,2016;12(4):438-45.
16 Ding D,Zhao Q,Guo Q,et al.The Shanghai aging study:study design,baseline characteristics,and prevalence of dementia[J].Neuroepidemiology,2014;43(2):114-22.
17 Cummings JL,Morstorf T,Zhong K.Alzheimer's disease drug development pipeline:few candidates,frequent failures[J].Alzheimers Res Ther,2014;6(4):37.
18 Deguil J,Ravasi L,Lamberty Y,et al.Early development of symptomatic drugs in AD:a systematic review of the use of biomarkers[J].CNS Neurol Disord Drug Targets,2016;15(7):823-36.
19 Hayashi AM.Thriving in a big data world[J].MIT Sloan Manag Rev,2014;55(2):35-9.
20 Khachaturian AS,Meranus DH,Kukull WA,et al.Big data,aging,and dementia:pathways for international harmonization on data sharing[J].Alzheimers Dement,2013;9(5suupl):S61-2.
21 Ashbrook DG,Williams RW,Lu L,et al.Joint genetic analysis of hippocampal size in mouse and human identifies a novel gene linked to neurodegenerative disease[J].BMC Genomics,2014;15:850.
22 NIH partnership launches big data portal for AD drug discovery[J].J Nucl Med,2015;56(4):10N.
23新华.大数据“约战”痴呆症[J].健康,2015;8:72-3.
24 Allen GI,Amoroso N,Anghel C,et al.Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease[J].Alzheimers Dement,2016;12(6):645-53.
25 Hofmann-Apitius M.Is dementia research ready for big data approaches[J]?BMC Med,2015;13:145.
26熊玮仪,吕筠,郭彧,等.大型前瞻性队列研究实施现况及其特点[J].中华流行病学杂志,2014;35(1):93-6.
27 Weuve J,Proust-Lima C,Power MC,et al.MELODEM Initiative.Guidelines for reporting methodological challenges and evaluating potential bias in dementia research[J].Alzheimers Dement,2015;11(9):1098-109.
2 Raghupathi W,Raghupathi V.Big data analytics in healthcare:promise and potential[J].Health Inf Sci Syst,2014;2:3.
3 Fregnac Y.Big data and the industrialization of neuroscience:a safe roadmap for understanding the brain[J]?Science,2017;358(6362):470-7.
4中华人民共和国科学技术部.科技部关于发布国家重点研发计划精准医学研究等重点专项2016年度项目申报指南的通知[EB/OL].http://www.most.gov.cn/tztg/201603/t20160308_124542.htm
5中华人民共和国中央人民政府.国务院办公厅印发《关于促进和规范健康医疗大数据应用发展的指导意见》[EB/OL].http://www.gov.cn/xinwen/2016-06/24/content_5085211.htm
6 Castro-Chavira SA,Fernandez T,Nicolini H,et al.Genetic markers in biological fluids for aging-related major neurocognitive disorder[J].Curr Alzheimer Res,2015;12(3):200-9.
7 Chan KY,Wang W,Wu JJ,et al.Epidemiology of Alzheimer's disease and other forms of dementia in China,1990-2010:a systematic review and analysis[J].Lancet,2013;381(9882):2016-23.
8 Alzheimr's Association.2015 Alzheimer's disease facts and figures[J].Alzheimers Dementia J Alzheimers Assoc,2015;11(3):332-84.
9 World Alzheimer Report 2015.The global impact of dementia[EB/OL].http://www.worldalzreport 2015.org
10谭琳.中国人口老龄化发展趋势预测研究报告[J].中国妇运,2007;(2):15-8.
11秦晓明.神经内科门诊患者认知障碍的横断面调查研究[J].中国现代药物应用,2014;(8):234-5.
12 Lehallier B,Essioux L,Gayan J,et al.Alzheimer's disease neuroimaging initiative.Combined plasma and cerebrospinal fluid signature for the prediction of midterm progression from mild cognitive impairment to Alzheimer disease[J].JAMA Neurol,2016;73(2):203-12.
13 Sosa AL,Albanese E,Stephan BC,et al.Prevalence,distribution,and impact of mild cognitive impairment in Latin America,China,and India:a 10/66 population-based study[J].PLoS Med,2012;9(2):e1001170.
14 Jack CR Jr,Therneau TM,Wiste HJ,et al.Transition rates between amyloid and neurodegeneration biomarker states and to dementia:a population-based,longitudinal cohort study[J].Lancet Neurol,2016;15(1):56-64.
15 Pase MP,Beiser A,Aparicio H,et al.Interarm differences in systolic blood pressure and the risk of dementia and subclinical brain injury[J].Alzheimers Dement,2016;12(4):438-45.
16 Ding D,Zhao Q,Guo Q,et al.The Shanghai aging study:study design,baseline characteristics,and prevalence of dementia[J].Neuroepidemiology,2014;43(2):114-22.
17 Cummings JL,Morstorf T,Zhong K.Alzheimer's disease drug development pipeline:few candidates,frequent failures[J].Alzheimers Res Ther,2014;6(4):37.
18 Deguil J,Ravasi L,Lamberty Y,et al.Early development of symptomatic drugs in AD:a systematic review of the use of biomarkers[J].CNS Neurol Disord Drug Targets,2016;15(7):823-36.
19 Hayashi AM.Thriving in a big data world[J].MIT Sloan Manag Rev,2014;55(2):35-9.
20 Khachaturian AS,Meranus DH,Kukull WA,et al.Big data,aging,and dementia:pathways for international harmonization on data sharing[J].Alzheimers Dement,2013;9(5suupl):S61-2.
21 Ashbrook DG,Williams RW,Lu L,et al.Joint genetic analysis of hippocampal size in mouse and human identifies a novel gene linked to neurodegenerative disease[J].BMC Genomics,2014;15:850.
22 NIH partnership launches big data portal for AD drug discovery[J].J Nucl Med,2015;56(4):10N.
23新华.大数据“约战”痴呆症[J].健康,2015;8:72-3.
24 Allen GI,Amoroso N,Anghel C,et al.Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease[J].Alzheimers Dement,2016;12(6):645-53.
25 Hofmann-Apitius M.Is dementia research ready for big data approaches[J]?BMC Med,2015;13:145.
26熊玮仪,吕筠,郭彧,等.大型前瞻性队列研究实施现况及其特点[J].中华流行病学杂志,2014;35(1):93-6.
27 Weuve J,Proust-Lima C,Power MC,et al.MELODEM Initiative.Guidelines for reporting methodological challenges and evaluating potential bias in dementia research[J].Alzheimers Dement,2015;11(9):1098-109.